Vir Biotechnology, Inc. VIR
Powering the Immune System to Transform Lives.
Vir Biotechnology, Inc. (including its subsidiaries, referred to as "Vir Bio," "the Company," "we," "our" or "us") is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer.
These diseases represent formidable challenges to human health. Under normal conditions, our immune system is naturally equipped to protect us by identifying and eradicating both cancer cells and viruses. However, these threats have evolved sophisticated mechanisms to evade our immune defenses. When cancer cells or viruses successfully bypass our immune system, they have the potential to cause diseases that may be life-threatening. We are focused on developing therapies that enhance the immune system's ability to overcome these evasion tactics, effectively powering the immune system to combat viruses and fight cancer.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $68.6M | $74.2M | $86.2M | $1.62B | $1.10B | $76.4M | $8.1M | $10.7M | $2.7M | — |
| Cost of revenue | $26.0K | $845.0K | $2.8M | $146.3M | $65.9M | $0 | $0 | — | — | — |
| Gross profit | $68.5M | $73.4M | $83.4M | $1.47B | $1.03B | $76.4M | $8.1M | — | — | — |
| R&D | $456.0M | $506.5M | $579.7M | $474.6M | $448.0M | $302.4M | $148.5M | $100.2M | $62.5M | — |
| SG&A | $92.1M | $119.0M | $174.4M | $161.8M | $160.8M | $70.9M | $37.6M | $29.1M | $21.7M | — |
| Total operating expenses | $547.9M | $661.4M | $770.5M | $782.7M | $674.7M | $373.3M | $186.1M | $129.4M | $84.2M | — |
| Operating income | -$479.3M | -$587.2M | -$684.3M | $833.1M | $420.8M | -$297.0M | -$178.0M | -$118.7M | -$81.5M | — |
| Pre-tax income | -$437.8M | -$523.1M | -$628.2M | $754.3M | $549.8M | -$298.6M | -$174.5M | -$116.4M | -$80.8M | — |
| Income tax | $217.0K | $1.1M | $13.1M | $238.4M | $21.2M | $54.0K | $154.0K | $480.0K | $10.9M | — |
| Net income | -$438.0M | -$522.0M | -$615.1M | $515.8M | $528.6M | -$298.7M | -$174.7M | -$115.9M | -$69.9M | — |
| EPS, basic | -3.16 | -3.83 | -4.59 | 3.89 | 4.07 | -2.51 | -5.76 | — | — | — |
| EPS, diluted | -3.16 | -3.83 | -4.59 | 3.83 | 3.96 | -2.51 | -5.76 | -15.12 | -32.45 | — |
| Shares, diluted (wtd. avg.) | $138.5M | $136.2M | $134.1M | $134.8M | $133.4M | $119.2M | $30.3M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $232.2M | $222.9M | $241.6M | $868.0M | $363.4M | $451.5M | $122.8M | $59.4M | $188.9M | $14.1M |
| Short-term investments | $228.8M | $678.1M | $1.27B | $1.52B | $217.2M | $300.3M | $274.1M | $50.8M | — | — |
| Receivables | — | — | — | $0 | $773.1M | $0 | — | — | — | — |
| Total current assets | $514.1M | $1.04B | $1.59B | $2.52B | $1.56B | $772.4M | $403.0M | $117.8M | — | — |
| Property, plant and equipment | $55.6M | $63.2M | $96.0M | $105.6M | $42.8M | $17.9M | $16.3M | $12.3M | — | — |
| Goodwill | $16.9M | $16.9M | $16.9M | $16.9M | $16.9M | $16.9M | $16.9M | $16.9M | — | — |
| Other intangibles | $7.8M | $8.1M | $22.6M | $32.8M | $33.3M | $33.8M | $35.7M | $36.9M | — | — |
| Total assets | $1.00B | $1.40B | $1.92B | $2.80B | $1.95B | $918.8M | $512.1M | $191.6M | — | — |
| Accounts payable | $9.8M | $5.1M | $6.3M | $6.4M | $6.5M | $5.1M | $5.9M | $6.5M | — | — |
| Total current liabilities | $92.8M | $119.7M | $175.4M | $511.0M | $341.2M | $99.1M | $59.2M | $39.9M | — | — |
| Total liabilities | $237.5M | $248.4M | $328.8M | $724.1M | $522.4M | $201.9M | $88.1M | $61.6M | — | — |
| Retained earnings | -$1.20B | -$759.8M | -$237.8M | $377.2M | -$138.6M | -$667.2M | -$368.5M | -$193.8M | — | — |
| Total equity | $765.3M | $1.15B | $1.59B | $2.08B | $1.43B | $716.9M | $423.9M | -$179.2M | -$68.9M | -$8.0M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$391.8M | -$446.4M | -$778.8M | $1.66B | -$47.6M | -$190.9M | -$129.6M | -$94.1M | -$66.4M | — |
| Depreciation and amortisation | $11.7M | $14.6M | $19.5M | $6.8M | $5.3M | $4.4M | $3.3M | $1.6M | $255.0K | — |
| Stock-based compensation | $49.1M | $78.5M | $111.3M | $102.1M | $83.8M | $27.6M | $8.7M | $5.1M | $4.8M | — |
| Capital expenditure | $4.8M | $7.3M | $21.6M | $68.0M | $21.8M | $6.5M | $8.9M | $8.2M | $2.7M | — |
| Investing cash flow | $310.4M | $499.4M | $164.6M | -$1.19B | -$140.8M | -$9.9M | -$256.2M | -$60.4M | -$30.0M | — |
| Financing cash flow | $3.8M | $4.4M | $7.5M | $34.8M | $100.3M | $529.5M | $449.2M | $25.0M | $271.2M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-025379.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $236.38B | 30.7x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $187.23B | 22.3x | 2.4% |
| MRNA | Moderna, Inc. | $58.11B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $45.01B | — | — |
| BIIB | BIOGEN INC. | $32.60B | 25.1x | 2.2% |
| SCNI | Scinai Immunotherapeutics Ltd. | $25.80B | — | 99.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $15.82B | 33.3x | 21.4% |
| EXEL | EXELIXIS, INC. | $14.62B | 21.2x | 7.0% |